Protein-altering germline mutations implicate novel genes related to lung cancer development
Xuemei Ji(The Ohio State University), Erik H.F.M. van der Heijden(Radboud University Nijmegen), Adonina Tardón(Universidad de Oviedo), Stephen Lam(University of British Columbia), Jinyoung Byun(Dartmouth College), Younghun Han(University of New Mexico), Angeline S. Andrew(Dartmouth College), Melinda C. Aldrich(Vanderbilt University Medical Center), Dakai Zhu(Baylor College of Medicine), Natasha B. Leighl(Princess Margaret Cancer Centre), Lynne R. Wilkens(University of Hawaiʻi at Mānoa), Lei Song(Nantong University), Nancy Diao(Harvard University), Guillermo Fernández‐Tardón(Universidad de Oviedo), Neil E. Caporaso(Unknown), Yonathan Brhane(University of Toronto), Ruyang Zhang(Hunan Agricultural University), Demetrius Albanes(National Cancer Institute), Ivan P. Gorlov(Dartmouth College), Mattias Johansson(Centre international de recherche sur le cancer), John K. Field(University of Liverpool), Xiangjun Xiao(Dartmouth College), Anders Mellemgaard(AstraZeneca (United Kingdom)), Konstantin H. Dragnev(Dartmouth Cancer Center), Loı̈c Le Marchand(University of Hawaiʻi at Mānoa), Rayjean J. Hung, Ana Fernández‐Somoano(Universidad de Oviedo), Christopher A. Haiman(University of Southern California), William S. Bush(Case Western Reserve University), Matthew B. Schabath(Moffitt Cancer Center), Heike Bickeböller(Nephrologisches Zentrum Goettingen), Stig E. Bojesen(University of Copenhagen), Walid Saliba(Technion – Israel Institute of Technology), Yohan Bossé(Institut universitaire de cardiologie et de pneumologie de Québec), Olga Y. Gorlova(Dartmouth College), Robert Carreras‐Torres(Institut de Biologia Evolutiva), Semanti Mukherjee(Zucker Hillside Hospital), Shan Zienolddiny(National Institute of Occupational Health), Philip Lazarus(University at Buffalo, State University of New York), Gad Rennert(Technion – Israel Institute of Technology), David C. Christiani(Harvard University), Philippe Joubert(Institut universitaire de cardiologie et de pneumologie de Québec), Li Su(University of Cambridge), Geoffrey Liu(Princess Margaret Cancer Centre), Chu Chen(Yunnan University of Finance And Economics), Jakob Sidenius Johansen(Gentofte Hospital), Lambertus FA. Kiemeney(Radboud University Nijmegen), Angela Cecilia Pesatori(University of Milan), Maria Teresa Landi(National Cancer Institute), Pier Alberto Bertazzi(University of Milan)
Cited by 51
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k